Rockville, MD – The Pfizer-CCOGC Biospecimen Repository has been open for release since September 2013. In year one, the Pfizer-CCOGC Biospecimen Repository has sold 1000 samples to investigators. Each application is evaluated based on scientific merit.
Quality control and assessment of randomly selected samples from the Pfizer-CCOGC Biospecimen Repository, representing 10% of all cases submitted, has been completed. The diagnostic classification of almost 89% of submitted specimens was corroborated by in-depth re-review by a panel of independent veterinary pathologists. Secondly, the proportion of specimens yielding nucleic acid considered being of suitable quality for most downstream genomics applications was 89.4% for tumor DNA, 92.1% for tumor RNA and 99.5% for blood DNA.
The Pfizer-CCOGC Biospecimen Repository currently houses over 60,000 samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and hemangiosarcoma. Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA collection tubes).
Formed in 2004, the Canine Comparative Oncology and Genomics Consortium (CCOGC) is a group of veterinary and human medical and radiation oncologists, pathologists, surgeons, geneticists, and cellular and molecular biologists who share the common goals of facilitating collaborations across disciplines, focusing on the problem of cancer in dogs. Priorities of the CCOGC include advocacy for the field of Comparative Oncology, expansion of available canine-specific research reagents, and the development of a biospecimen repository.
With a lead gift from Pfizer Animal Health and substantial donations from the AKC-Canine Health Foundation and Morris Animal Foundation, sample collection began in 2007. Standard operating procedures for tissue/sample collection and storage were established to maximize consistency and are subject to annual review. Informed owner consent and IACUC approval has been obtained prior to collection and samples have been de-identified at the collecting site. Each case in the repository is represented by tumor and normal tissue, collected and processed in ethanol and two frozen formats (flash frozen and OCT embedded). The repository follows many aspects of the organization and structure of the proposed National Biospecimen Network Blueprint. A sample shipping and collection database (Tissue Tracker) is used for real time connection between CCOGC collection sites and the central physical bank (Pfizer-CCOGC Biospecimen Repository) housed in Frederick, MD. Patient clinical information is contemporarily collected and logged as part of the biorepository effort and is available along with the samples.
In addition to providing access to banked canine cancer biospecimens, the CCOGC is also able to offer its tissue collection infrastructure to third parties who wish to request specific prospective collection of tissues. Further information may be obtained by contacting email@example.com.